Hope, Progress, and the Future of Cholangiocarcinoma Research The 2026 Cholangiocarcinoma Foundation Conference brought together patients, caregivers, clinicians, researchers, advocates, and industry partners in Salt Lake City to share the latest progress in cholangiocarcinoma research and care.1 A key message from the conference was clear: research in cholangiocarcinoma is advancing rapidly, but access to appropriate testing, clinical trials, and expert care remains essentia

On December 12, 2025, members of the Canadian Cholangiocarcinoma Collaborative (C3) travelled to Houston, Texas and attended the Cholangiocarcinoma Foundation's (CCF) Houston Day Symposium to connect, learn, and bring back the latest advances in biliary tract cancer (BTC) research and care to our Canadian community. Houston is one of the world’s leading hubs for cholangiocarcinoma research, home to high-volume centres such as MD Anderson Cancer Center and Houston Methodist C

I wanted to share a short summary of key themes and insights from the 2025 Canadian Cancer Research Conference (CCRC), held in Calgary earlier this month. While the event covered all cancer types, many sessions touched on topics that are especially relevant for those affected by cholangiocarcinoma and other rare or gastrointestinal cancers. I attended alongside 3 C3 sponsored patients: Cynthia Mitchell, Corri Desaulniers, and Heba Affifi. L to R: Christine Lafontaine, Cynth

Over the past few days, I had the absolute privilege of spending time with patients, caregivers, colleagues, mentors, and new friends. It was an unforgettable experience. ​ Our Meet C3 Conference held from April 4-6 in Toronto, Ontario was a tremendous success , with over 100 unique in-person attendees and more than 60 joining online – on a weekend! For a rare cancer community, that kind of turnout speaks volumes. More importantly, it offered something invaluable: hope—to tho